Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

By Kuroi Katsumasa   Shimozuma Kojiro   Ohashi Yasuo   Hisamatsu Kazufumi   Masuda Norikazu   Takeuchi Ayano   Aranishi Toshihiko   Morita Satoshi   Ohsumi Shozo   Hausheer Frederick  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1071-1080

Springer Publishing Company

Access to resources Recommend Favorite

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

By Suh Kwang   Kim Joo   Kim Do   Kim Young   Lee Chulho   Choi Sungho  

Annals of Surgical Oncology, Vol. 13, Iss. 11, 2006-11 ,pp. : 1379-1385

Springer Publishing Company

Access to resources Recommend Favorite

Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study

By Demiray Mutlu   Ulukaya Engin Engin   Arslan Murat   Gokgoz Sehsuvar   Saraydaroglu Ozlem   Ercan Ilker   Evrensel Turkkan   Manavoglu Osman  

Cancer Investigation, Vol. 24, Iss. 7, 2006-09 ,pp. : 669-676

Informa Healthcare

Access to resources Recommend Favorite

The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen

By Cameron D.A.   Ritchie A.A.   Miller W.R.  

European Journal of Cancer, Vol. 37, Iss. 12, 2001-08 ,pp. : 1545-1553

Elsevier

Access to resources Recommend Favorite

Chemotherapy For Metastatic Breast Cancer--When is Enough Enough?

By Stockler M.   Wilcken N.   Coates A.  

European Journal of Cancer, Vol. 33, Iss. 13, 1997-11 ,pp. : 2147-2148

Elsevier

Access to resources Recommend Favorite